Research platforms

In addition to the direct funding provided to researchers in the form of awards, grants, and scholarships, we also fund important research platforms, investing $1,000,000 in 2015, an increase of almost $171,000.

These platforms include our commitment to our lung cancer trials groups (ALTG and TACT), and our IPF and bronchiectasis registries.

Lung Cancer Trials Groups

2015 was a year of growth and momentum for the Lung Foundation’s lung cancer research initiative Australasian Lung cancer Trials Group (ALTG). We have more than 500 clinical members working on:

  • new trials
  • activities to translate research into practice
  • raising awareness of the unmet need in lung cancer research.

Expanding on the work done by ALTG, in September we launched the Thoracic Alliance for Cancer Trials (TACT), a unique global collaboration to develop and initiate clinical trials through its global network that would otherwise not be feasible.

Australia Idiopathic Pulmonary Fibrosis Registry 

The depth of data collected by the Australian Idiopathic Pulmonary Fibrosis (IPF) Registry on the over 630 participants continues to increase. This comprehensive data collection, together with the linked biobank with blood samples collected from many of these participants, has proven to be of strong interest to researchers and research funders.

Biobank samples and registry data are being shared under a collaborative international study with the University of Colorado. This global biobank will be used to examine genetic factors contributing to IPF.

Click here for more information.

Australian Bronchiectasis Registry

The Australian Bronchiectasis Registry is a non-commercial research project that has been created by a group of Australian respiratory specialist doctors together with Lung Foundation Australia.

The main aims of this registry are to identify and collect health information from patients with non-Cystic Fibrosis (non-CF) Bronchiectasis for doctors to research the causes and to improve treatments. Ultimately, we want to discover a cure or vaccination for this debilitating disease which affects both children and adults.

Apart from the native registry data, the Department of Human Services have given us access to Medicare and PBS data. By combining these data, we can provide prospective researchers a rare and exceptional opportunity to learn more about healthcare utilisation and costs associated with Bronchiectasis as well as access to patient behaviours and outcomes.

Click here to read more.